AbCellera Biologics (ABCL) Total Non-Current Liabilities (2020 - 2026)

AbCellera Biologics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $321.7 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 30.88% year-over-year to $321.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.7 million (up 30.88% YoY) and the FY2025 annual result came in at $325.7 million, up 42.96% from the prior year.
• Total Non-Current Liabilities was $321.7 million for Q1 2026 at AbCellera Biologics, down from $325.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $328.0 million in Q2 2025 and bottomed at $159.8 million in Q2 2022.
• A 5-year average of $237.8 million and a median of $227.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 106.45% — and 2024, when it increased 3.45%.
• AbCellera Biologics' Total Non-Current Liabilities stood at $189.3 million in 2022, then gained by 14.5% to $216.8 million in 2023, then climbed by 5.12% to $227.9 million in 2024, then soared by 42.96% to $325.7 million in 2025, then declined by 1.23% to $321.7 million in 2026.
• Business Quant data shows ABCL's Total Non-Current Liabilities at $321.7 million in Q1 2026, $325.7 million in Q4 2025, and $323.2 million in Q3 2025.